Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.

BACKGROUND: The failure to respond to chemotherapy is a major obstacle in the successful treatment of breast cancer. We have previously shown that anti-HER-2 antisense oligonucleotide (AS HER-2 ODN) treatment was able to sensitize breast cancer cells to various chemotherapeutic agents in vitro irres...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rait, Antonina S., Pirollo, Kathleen F., Xiang, Laiman, Ulick, David, Chang, Esther H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2002
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2040013/
https://ncbi.nlm.nih.gov/pubmed/12435858
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak